Expert Interview
Discussing Iovance's TIL therapy AMTAGVI (lifileucel) recently FDA approved for unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody.
Ticker(s): IOVAInstitution: University of Washington
- Director of the Melanoma and Renal Cancer Team at Fred Hutchinson Cancer Center and Professor of Medical Oncology at the University of Washington School of Medicine
- Treats ~ 100 patients per year with melanoma, ~50 of which are Stage IV
- Clinical interest in advanced skin cancers, including melanoma, ocular melanoma, Merkel cell carcinoma and other non-melanoma skin cancers; Research interest in novel immunotherapies, targeted therapies, and intra-tumoral immunotherapy.
The phase 2 C-144-01 trial showed early and durable responses in advanced melanoma patients treated with Lifileucel. Can you elaborate on the significance of these findings, especially considering the challenges faced in treating patients who have progressed on checkpoint inhibitors?
Added By: slingshot_insightsWith an objective response rate of 31.4% and a substantial reduction in tumor burden observed, how does Lifileucel's performance compare to existing treatments for advanced melanoma?
Added By: slingshot_insightsThe trial revealed different patterns of response and their impact on long-term survival. Could you discuss how these patterns might influence treatment decisions and patient outcomes?
Added By: slingshot_insightsSeveral patients converted to a complete response more than a year after treatment. What does this indicate about the long-term efficacy and potential of Lifileucel in melanoma therapy?
Added By: slingshot_insightsHow do factors like lactate dehydrogenase (LDH) levels and the number of lesions influence the efficacy of Lifileucel, and what does this mean for patient selection?
Added By: slingshot_insightsConsidering the safety profile of Lifileucel, particularly in relation to lymphodepletion and IL-2, how should clinicians approach the management of treatment-emergent adverse effects?
Added By: slingshot_insightsWhere do you see AMTAGVI fitting into the current treatment paradigm for advanced melanoma, especially for patients with resistance to checkpoint inhibitors?
Added By: slingshot_insightsNow that AMTAGVI is FDA approved, what future directions might research and clinical application take?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
